Guggenheim upgraded Neumora Therapeutics (NMRA) to Buy from Neutral with a $14 price target following the “compelling” preclinical obesity data reported by the company. The firm views the company’s NLRP3i program in obesity and related disorders as “a clear driver to value creation,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Promising Preclinical Data and Strategic Focus Support Buy Rating for Neumora Therapeutics
- Neumora Therapeutics Begins Phase 1 Study for NMRA-898
- Neumora Therapeutics initiates Phase 1 clinical study of NMRA-988
- Neumora Reports Positive Preclinical Results for NMRA-215
- Neumora Therapeutics’ NMRA-215 shows weight loss efficacy